Hurotics
Develops wearable robotics and exosuits for gait rehabilitation and assistance using AI to support mobility.
Website: https://www.hurotics.com/en/
Cover Block
Open sources
| Field | Value |
|---|---|
| Name | Hurotics |
| Tagline | Develops wearable robotics and exosuits for gait rehabilitation and assistance using AI to support mobility. |
| Headquarters | Seoul, South Korea [The Seoul Economic Daily, October 2026] |
| Founded | 2022 [Crunchbase] |
| Stage | Series A [The Seoul Economic Daily, October 2026] |
| Business Model | Hardware + Software |
| Industry | Deeptech |
| Technology | Robotics |
| Geography | East Asia |
| Growth Profile | Venture Scale |
| Founding Team | Academic Spinout [The Seoul Economic Daily, October 2026] |
| Funding Label | Series A |
| Total Disclosed Funding | More than ₩33.5 billion, approximately $24.8 million (estimated) [The Seoul Economic Daily, October 2026] |
Links
Open sources
- Website: https://www.hurotics.com/en/
What an Investor Needs First
PUBLIC Hurotics is a Seoul-based wearable robotics company building soft exosuits for gait rehabilitation, and it merits investor attention now because it has moved from product development into early clinical commercialization and closed a sizable Series A in October 2026 [Asiae, October 2026] [The Seoul Economic Daily, October 2026]. Founded in 2022, the company was started by Lee Gi-wook, identified in public sources as a Chung-Ang University mechanical engineering professor, which places Hurotics in the familiar Korean academic spinout pattern but with unusually fast progress to market for a medical robotics company [Crunchbase] [The Seoul Economic Daily, October 2026].
Its lead product, H-Medi, is a wearable exosuit for walking assistance and gait rehabilitation; public reporting describes it as lightweight at roughly 4.5 kilograms, built with flexible materials rather than a rigid frame, and commercialized in September 2025 [donga.com, December 2025] [Founderland, October 2026] [Asiae, October 2026]. That form factor matters because the product case appears to rest less on novel robotics claims alone and more on usability in real rehab settings, including quicker donning and better tolerance for patients with stiffness or joint deformities, according to product coverage [donga.com, December 2025].
The early go-to-market signal is clinical adoption rather than broad scale. As of October 2026, H-Medi had been adopted by Sinchon Severance Hospital, Chung-Ang University Hospital, and Korea University Hospital, and separate public database coverage also points to an export to the University of Illinois Chicago for stroke rehabilitation research and physical therapy use in June 2026 [Asiae, October 2026] [dealroom.co].
The capital base is now meaningful for a company at this stage. Hurotics raised a reported ₩25 billion Series A, about $18.6 million, led by Atinum Investment, with participation from a mix of venture and strategic backers including Stonebridge Ventures, Doosan Investment, Aju IB Investment, Wonik Investment Partners, Daewoong Pharmaceutical, NAVER, Lotte, and Industrial Bank of Korea; cumulative disclosed funding was reported at more than ₩33.5 billion, or about $24.8 million (estimated, based on reported cumulative funding and contemporaneous USD conversion) [The Seoul Economic Daily, October 2026] [Founderland, October 2026]. The business model is best understood as hardware plus software sold first into hospitals and rehabilitation providers, with a longer-dated expansion path into everyday mobility assistance through H-Care, which the company has said is in development [Asiae, October 2026] [HUROTICS].
Over the next 12 to 18 months, the main watchpoints are whether hospital adoption converts into repeatable deployment beyond flagship institutions, whether overseas regulatory and distribution efforts progress as management has indicated, and whether H-Care becomes a credible second product rather than a forward-looking adjacency [Asiae, October 2026] [The Seoul Economic Daily, October 2026]. The evidence so far supports a real company with real clinical placements and real financing, but the public record is still thin on revenue, unit volumes, and reimbursement dynamics, which keeps the underwriting case anchored to execution rather than market narrative [Asiae, October 2026] [The Seoul Economic Daily, October 2026].
Partially corroborated -- Built primarily from named-publisher coverage and company materials, with several core claims corroborated across Asiae, The Seoul Economic Daily, donga.com, and Founderland, but limited independent public disclosure on commercial metrics.
Taxonomy Snapshot
| Axis | Value |
|---|---|
| Stage | Series A |
| Business Model | Hardware + Software |
| Industry / Vertical | Deeptech |
| Technology Type | Robotics |
| Geography | East Asia |
| Growth Profile | Venture Scale |
| Founding Team | Academic Spinout |
| Funding | Total disclosed approximately $24.8 million [The Seoul Economic Daily, October 2026] |
Inside the Company
PUBLIC
Hurotics appears to be an academic spinout taking a fairly direct route from lab work to commercialization. The company is based in Seoul, South Korea and was founded in 2022, according to its Crunchbase profile, while its public website presents the business as a wearable robotics company focused on gait rehabilitation through exosuits and AI-based real-time walking analysis [Crunchbase] [HUROTICS]. Public materials identify founder Lee Gi-wook as the central figure behind the company, and Crunchbase lists him as founder and CEO; the same source also notes prior postdoctoral experience at Harvard University [Crunchbase].
The public record is still thin on corporate detail beyond that core identity. Hurotics' website shows an English-language corporate presence with product, technology, research, partner, and careers pages already in market, which is usually a useful signal that the company has moved beyond pure lab-stage formation, even if the site does not itself establish operating scale [HUROTICS]. The website also centers H-Medi as the flagship product and describes the company's broader aim as building trusted wearable robots for human movement support, which is consistent with Crunchbase's categorization of the business as a robotics startup [HUROTICS] [Crunchbase].
On milestones, the company website indicates a productized posture through dedicated H-Medi, support, and purchase or demo pathways, while Crunchbase provides the dated anchor of a 2022 founding and a subsequently tracked financing history [HUROTICS] [Crunchbase]. Within the limits of company and database sources, the chronology that can be stated cleanly is narrow but coherent: Hurotics was founded in 2022 in Seoul, built a public commercial web presence around H-Medi, and by the time of its current Crunchbase profile had become legible enough to outside capital databases to be tracked as a funded robotics company [Crunchbase] [HUROTICS].
Partially corroborated -- Based on Crunchbase and the company website, with company identity and founding details only partially corroborated by independent public records.
Under the Hood
MIXED Product and Technology
Hurotics is building around a specific form factor bet: a soft, wearable exosuit for gait rehabilitation rather than a rigid external frame. Public materials and press coverage describe H-Medi as a clothing-like rehabilitation robot that uses flexible materials and textiles, with the company positioning it as data-driven gait rehabilitation through wearable exosuits [HUROTICS]. Third-party coverage adds that the device weighs about 4.5 kilograms and is designed so patients with joint deformities or stiffness can wear it with less burden than a frame-based system, while one report says it can be put on in under two minutes [donga.com, December 2025] [Founderland, October 2026].
The product appears to have moved beyond prototype status and into early clinical use. Asiae reported that H-Medi was commercialized in September 2025 and had been adopted by Sinchon Severance Hospital, Chung-Ang University Hospital, and Korea University Hospital by October 2026 [Asiae, October 2026]. Separate public references also place the system in hospital settings and describe an export to the University of Illinois Chicago in June 2026 for stroke rehabilitation research and physical therapy training [dealroom.co] [Asiae, October 2026]. The company website highlights bio-inspired tendon-driven robotics and AI-based real-time gait analysis, while open roles across firmware, motor control, wearable algorithms, QA, and information security suggest a vertically integrated hardware-software stack rather than a pure device reseller [HUROTICS] [HUROTICS, inferred from job postings].
What remains less settled in public evidence is the boundary between demonstrated capability and broader platform ambition. Company materials reference core technologies such as bio-inspired tendon-driven robotics and AI motion analysis, but details on model performance, sensing architecture, remote data features, and clinical outcome improvements are not established in the sources reviewed [HUROTICS]. Press reports also mention H-Care as a separate product aimed at everyday walking assistance, but the public record here is still descriptive rather than performance-based [Asiae, October 2026].
Partially corroborated -- Built from company website materials and single-source press coverage, with partial corroboration on device weight and hospital deployment.
Market Research
PUBLIC
This market matters now because rehabilitation providers and mobility-assistance companies are converging on lighter wearable robotics just as funding, clinical adoption, and aging-driven demand are pushing the category from lab work toward commercial deployment [Asiae, October 2026] [eDaily, October 2026] [donga.com, December 2025].
The difficulty is that no named third-party market-sizing report appears in the source set for soft exosuits, gait rehabilitation robotics, or wearable medical robotics specific to Hurotics' segment. On that record, any TAM, SAM, or SOM figure would be conjectural, so the public evidence supports a narrower conclusion: Hurotics is entering a clinically legible submarket where hospitals are already purchasing or trialing device-assisted gait rehabilitation, and where Korean media and investor coverage are beginning to treat wearable robotics as part of the country's broader deeptech financing cycle [Asiae, October 2026] [eDaily, October 2026] [The Seoul Economic Daily, October 2026].
The clearest demand signal in the available reporting is not a top-down market number but early institutional uptake. H-Medi was commercialized in September 2025, according to Asiae, and had reached Sinchon Severance Hospital, Chung-Ang University Hospital, and Korea University Hospital by October 2026 [Asiae, October 2026]. Dealroom also lists Severance, Chung-Ang University, and Korea University among hospitals reached by the product, which gives that adoption signal a second public source even if the exact commercial terms are not disclosed [dealroom.co]. That matters because rehabilitation hardware tends to face a long path from prototype credibility to routine clinical use, and hospital reference accounts often function as the first real screen for product-market fit.
Adjacent demand also broadens the category beyond acute clinical rehab. Public sources describe H-Medi as a soft exosuit for gait rehabilitation and describe H-Care as a separate product in development for everyday walking assistance rather than clinical care [Asiae, October 2026] [HUROTICS]. That suggests two nearby markets with different buying logic: provider-led rehabilitation equipment on one side, and mobility-assistance wearables for daily living on the other. Substitute categories include rigid exoskeletons, conventional physical therapy programs, orthotics, and lower-tech assistive devices. Hurotics' stated wedge, using textiles and flexible materials instead of a rigid external frame, appears aimed at improving wearability and patient comfort rather than replacing the entire rehabilitation stack [donga.com, December 2025].
The regulatory and macro backdrop is supportive, but still execution-heavy. eDaily described H-Medi as an MFDS Class 2 certified medical gait-rehabilitation soft exosuit, while Seoul Economic Daily reported that fresh Series A proceeds are intended to support overseas approvals and distribution [eDaily, October 2026] [The Seoul Economic Daily, October 2026]. In practice, that means the addressable market is gated less by abstract demand than by country-by-country clearance, reimbursement pathways, distributor buildout, and the evidence burden needed to convert clinician interest into standardized procurement. The June 2026 export to the University of Illinois Chicago for stroke-rehabilitation research and physical therapy training is directionally positive, but still reads as an early international foothold rather than proof of scaled cross-border commercialization [dealroom.co].
| Market lens | Public evidence | Analytical read |
|---|---|---|
| Clinical gait rehabilitation | H-Medi commercialized in September 2025 and adopted by named Korean hospitals by October 2026 [Asiae, October 2026] | This is the most evidenced near-term market, with hospitals as the clearest initial buyer set. |
| Everyday mobility assistance | Hurotics is developing H-Care for everyday walking assistance [Asiae, October 2026] [HUROTICS] | Larger potential user base, but commercialization timing and regulatory path are less clearly evidenced. |
| International research and training | H-Medi was exported to the University of Illinois Chicago in June 2026 for stroke rehabilitation research and physical therapy training [dealroom.co] | Useful for credibility and early channel testing, but not enough to establish repeatable overseas demand. |
| Korean deeptech capital formation | Hurotics' financing was covered in the context of rising deeptech investment in Korea [eDaily, October 2026] | Capital availability appears constructive for category development, though financing momentum is not the same as end-market demand. |
The table points to a market story built from bottom-up adoption markers rather than published sizing data. For investors, that makes clinical procurement evidence, repeat usage, and regulatory expansion more informative than any unsupported TAM headline would be.
Partially corroborated -- Section relies on named publisher reporting from Asiae, eDaily, The Seoul Economic Daily, donga.com, plus one single-source market-adjacency datapoint from Dealroom without a dated independent corroborating article.
Competition and Substitutes
MIXED
Hurotics appears positioned in the soft exosuit and gait-rehabilitation segment, where its closest practical alternatives are not named startup peers in the sourced record but a mix of hospital rehabilitation equipment, rigid exoskeleton systems, and conventional physical therapy workflows [HUROTICS] [donga.com, December 2025] [Exoskeleton Report].
The competitive map is clearer at the segment level than at the company level because the source set does not identify direct startup rivals by name. In clinical rehabilitation, Hurotics is selling against standard care pathways inside hospitals, which include therapist-led gait training and established rehab hardware already budgeted into provider settings [Asiae, October 2026] [Exoskeleton Report]. In wearable robotics, the more relevant distinction is form factor: H-Medi is described as using textiles and flexible materials rather than a rigid external frame, which places it in a softer, lower-bulk category than traditional frame-based exoskeleton approaches [donga.com, December 2025] [Exoskeleton Report]. Adjacent substitutes also matter. For some providers, the decision may not be between H-Medi and another exosuit at all, but between adding a wearable device or expanding therapist time and existing rehab equipment.
Where Hurotics seems to have an edge today is product design aligned to clinical usability, plus early institutional proof points. Public reporting says H-Medi weighs about 4.5 kilograms and can be donned in less than two minutes, both meaningful details in a rehab setting where setup time and patient comfort affect utilization, not just outcomes [Founderland, October 2026] [donga.com, December 2025]. The company also appears to have crossed an important early distribution threshold, with adoption reported at Sinchon Severance Hospital, Chung-Ang University Hospital, and Korea University Hospital, and an export to the University of Illinois Chicago for research and physiotherapist training [Asiae, October 2026] [dealroom.co]. That edge is promising but not yet fully durable. Hospital references can help with procurement credibility and clinician trust, but unless they convert into broader installed-base growth, published outcomes data, or reimbursement support, the advantage remains perishable.
Its defensibility also rests partly on founder-market fit and capital access. Lee Gi-wook is identified as a mechanical engineering professor at Chung-Ang University, which supports the view that Hurotics emerged from a research-driven talent base rather than a consumer-device play [Crunchbase] [The Seoul Economic Daily, October 2026]. The October 2026 Series A, led by Atinum Investment with participation from financial and strategic backers including Daewoong Pharmaceutical, NAVER, and Lotte, should improve Hurotics' ability to fund regulatory work, manufacturing, and distribution buildout [The Seoul Economic Daily, October 2026] [Founderland, October 2026]. Still, this is not the same as owning the channel. Strategic investors can open doors, but the public record here does not establish exclusive distribution rights, captive demand, or a reimbursement moat.
The main exposure is that Hurotics is still proving a category as much as a product. A flexible suit may be more wearable than a rigid exoskeleton, but that does not by itself settle the buying decision for hospitals, which often need evidence on clinical outcomes, workflow fit, service support, and budget justification before scaling deployments [donga.com, December 2025] [Asiae, October 2026]. The company is also exposed to adjacent categories it may not control, especially incumbent rehab equipment vendors and large medical-device groups with existing hospital sales coverage. Those players are not named in the sourced record, so it would be overstated to assign share or cite a direct head-to-head leader. The narrower point is enough: Hurotics has early adoption, but it does not yet appear to own the clinical channel it is entering.
Over the next 18 months, the most plausible competitive scenario is segmentation rather than winner-take-all consolidation. Hurotics could become a category leader in Korean hospital gait rehabilitation if overseas approvals progress and the existing hospital base converts into broader reference accounts and repeat procurement [Asiae, October 2026] [The Seoul Economic Daily, October 2026]. In that case, the likely winner if clinical validation and distribution execution hold is Hurotics itself [PUBLIC]. The likely loser if providers continue to prefer lower-complexity standard rehab workflows is not a named startup from the source set, but the broader soft-exosuit adoption thesis in acute and rehab care [PUBLIC]. That distinction matters. The competitive question is less whether Hurotics can outmarket a clearly identified startup rival today, and more whether it can turn early placements into a durable product category before incumbents or substitute workflows absorb the demand.
com, December 2025] [Exoskeleton Report] [Founderland, October 2026].
Opportunity
PUBLIC
If Hurotics executes on both clinical adoption and overseas clearance, the prize is not a niche rehab-device business but a durable position in wearable mobility robotics, starting with hospitals and potentially extending into daily-use walking assistance [Asiae, October 2026] [The Seoul Economic Daily, October 2026].
The most credible upside case is that Hurotics becomes a leading Asian platform for soft exosuits in gait rehabilitation, then uses that clinical foothold to expand into broader mobility assistance. The reason that outcome is reachable, rather than merely aspirational, is that the company already appears to have crossed several threshold events that matter in medical robotics: commercialization of H-Medi in September 2025, hospital adoption at named institutions, and a sizeable Series A led by Atinum with participation from both financial and strategic investors including Daewoong Pharmaceutical, NAVER, and Lotte [Asiae, October 2026] [The Seoul Economic Daily, October 2026]. The product itself also reads as differentiated on form factor, with reporting describing H-Medi as a lightweight soft exosuit of roughly 4.5 kilograms that uses flexible materials rather than a rigid frame, a design choice that could matter in rehab settings where comfort, fitting time, and patient tolerance affect actual usage [donga.com, December 2025] [Founderland, October 2026].
The plausible paths to outsized scale are still narrow, but they are visible in the public record.
| Scenario | What happens | Catalyst | Why it's plausible |
|---|---|---|---|
| Clinical standard in Korean gait rehab | H-Medi becomes a repeat-buy platform across major rehabilitation hospitals in South Korea, creating a domestic reference base strong enough to support broader procurement and training adoption | More named hospital deployments following the September 2025 commercialization, plus continued use at early adopters such as Severance, Chung-Ang University Hospital, and Korea University Hospital | H-Medi was reported commercialized in September 2025 and had already reached those hospitals by October 2026 [Asiae, October 2026] [dealroom.co] |
| Export-led rehab robotics expansion | Hurotics converts early academic and hospital credibility into overseas regulatory and distributor-led expansion for H-Medi | The company has publicly tied new funding to overseas approvals and distribution, and it already reported an export to the University of Illinois Chicago in June 2026 | The Series A proceeds were reported for overseas approvals and distribution, while UIC appears in public reporting as an early international research deployment [The Seoul Economic Daily, October 2026] [dealroom.co] |
| Dual-market mobility company | The company uses H-Medi's clinical validation to launch H-Care as a larger everyday walking-assistance product line, moving from episodic rehab budgets toward a broader mobility market | Successful development and mass production of H-Care, which management-linked coverage says is intended for everyday walking assistance | Public coverage states Hurotics is developing H-Care and that Series A capital will support its development and mass production [Asiae, October 2026] [The Seoul Economic Daily, October 2026] |
What would make this compound is not a consumer-style network effect, but an evidence and distribution flywheel. In rehab robotics, every incremental hospital site can do three things at once: validate safety and usability, create clinician familiarity, and generate more movement data around gait-assistance protocols. Public materials already suggest the first turn of that wheel is underway, with commercialization followed by adoption at named hospitals, and with the company hiring across control algorithms, firmware, production, quality, and reliability functions that fit a transition from prototype-heavy development toward scaled clinical deployment [Asiae, October 2026] [HUROTICS] [donga.com, December 2025]. If overseas approvals follow, that installed clinical base could also improve the launch odds for H-Care, because a company trusted by hospitals has a stronger starting position when it asks patients, partners, or distributors to trust a daily-use mobility product.
The size of the win is difficult to anchor precisely because no public market-sizing data or direct public comparable was provided in the source set. Even so, the disclosed financing offers one useful boundary: investors have already funded Hurotics to more than ₩33.5 billion cumulatively, including a ₩25 billion Series A, to pursue overseas approvals, distribution, and a second product line [The Seoul Economic Daily, October 2026]. If the export-led or dual-market scenarios above play out, the company could plausibly grow from a single-product Korean medtech into a strategic wearable-robotics platform that attracts follow-on growth capital or strategic interest at a meaningfully larger scale than today's disclosed funding base (scenario, not a forecast) [The Seoul Economic Daily, October 2026] [Asiae, October 2026]. The evidence does not yet support a tighter valuation case, but it does support the central upside claim: Hurotics has advanced beyond lab-stage robotics into early commercial proof points, and that is where unusually large outcomes in medical devices sometimes begin.
Partially corroborated -- This section relies primarily on Asiae, The Seoul Economic Daily, donga.com, Founderland, HUROTICS, and dealroom.co. Several core claims are corroborated by multiple public sources, but the section's upside framing also depends on forward-looking inferences and one source with limited date transparency.
Sources
Open sources
[The Seoul Economic Daily, October 2026] Wearable Robot Maker Hurotics Raises 25 Billion Won in … | https://en.sedaily.com/technology/2026/10/15/wearable-robot-maker-hurotics-raises-25-billion-won-in
[Crunchbase] Hurotics - Crunchbase Company Profile & Funding | https://www.crunchbase.com/organization/hurotics
[Asiae, October 2026] Hyurotics Raises 25 Billion Won in Series A Funding | https://www.asiae.co.kr/en/article/2026101508245845605
[donga.com, December 2025] Hurotics: Pioneering Gait Rehab with "Exosuits" as Light and Wearable as Clothing | https://www.donga.com/en/article/all/20251217/6015670/1
[Founderland, October 2026] HUROTICS raises $18.6M for medical exosuit technology | https://www.founderland.ai/articles/hurotics-raises-186m-for-medical-exosuit-technology-mv9qve23
[HUROTICS] HUROTICS | https://www.hurotics.com/en/
[eDaily, October 2026] VC’s Pick: Deep Tech on the Rise: From Robotics to Quantum Computing and SMRs | https://en.edaily.co.kr/news/eda202610175114/
[Exoskeleton Report] H-Medi | https://exoskeletonreport.com/product/h-medi/
Articles about Hurotics
- A 4.5-Kilogram Exosuit Is Walking Out of Korean Rehab Clinics — The Chung-Ang University spinout, backed by NAVER and Daewoong, is betting that textiles and cables can outmaneuver rigid exoskeletons.